ACM
ABVX

Aquatic Capital Management’s Abivax ABVX Stock Holding History

Aquatic Capital Management’s Portfolio ABVX Stock Details ABVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-26,608
Closed -$3.59M – 1307
2025
Q4 		$3.59M Buy
+26,608
New +$2.9M 0.1% 246

Other funds holding ABVX

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HI
Helikon Investments London, United Kingdom $2.65B AUM 79.03% 1-Year Est. Return

Aquatic Capital Management's ABVX Position: Q1 2026 in Review

Aquatic Capital Management sold out of Abivax (ABVX) in Q1 2026, closing a stake of 26,608 shares — an estimated $3.59M sold.

Aquatic Capital Management first reported a position in ABVX in Q4 2025 and held it in 1 quarter. The position peaked at $3.59M in Q4 2025. 254 funds tracked by Wall St. Rank hold ABVX as of Q1 2026.

  • Aquatic Capital Management reported no remaining Abivax position as of Q1 2026 after selling out during the quarter.
  • Aquatic Capital Management sold 26,608 Abivax shares in Q1 2026, an estimated $3.59M.
  • Aquatic Capital Management first reported a position in Abivax in Q4 2025 and held it in 1 quarter.
  • Aquatic Capital Management's Abivax position peaked at $3.59M in Q4 2025.
  • 254 funds tracked by Wall St. Rank held Abivax as of Q1 2026.

Based on Aquatic Capital Management's 13F filing for Q1 2026, filed 15 May 2026.